Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

Arthritis and Rheumatism

Volumn 48, Issue 8, 2003, Pages 2146-2154

  Cambridge, Geraldine ^a   Leandro, Maria J ^a   Edwards, Jonathan C W ^a,e   Ehrenstein, Michael R ^a   Salden, Martin ^b   Bodman Smith, Mark ^c   Webster, Anthony D B ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Euro Diagnostica BV   (Netherlands)

^c GUY S HOSPITAL   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e Centre for Rheumatology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BACTERIUM ANTIBODY; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RHEUMATOID FACTOR; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; LYMPHOCYTE DEPLETION; MALE; PATHOGENESIS; PRIORITY JOURNAL; RELAPSE; RHEUMATOID ARTHRITIS; SEROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; C-REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PREDNISOLONE; RECURRENCE; RHEUMATOID FACTOR;

EID: 0041571732     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11181     Document Type: Article

References (34)

1. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? II. T-cell-independent mechanisms from beginning to end. Arthritis Rheum 2002;46:298-308.
2. Edwards JCW, Cambridge G, Abrahams VM. Do self-perpetuating B-lymphocytes drive human autoimmune disease? Immunology 1999;97:1868-96.
3. Stastny P. Association of the B-lymphocyte alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978;298:869-72.
4. Mitchison NA, Wedderburn LR. B-cells in autoimmunity. Proc Natl Acad Sci U S A 2000;97:8750-1.
5. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B-lymphocytes. J Exp Med 1991;173:487-9.
6. Abrahams VM, Cambridge G, Edwards JCW. Induction of tumor necrosis factor α production by human monocytes: a key role for Fcγ receptor type IIIa in rheumatoid arthritis. Arthritis Rheum 2000;43:608-16.
7. Bhatia A, Blades S, Cambridge G, Edwards JCW. Differential distribution of FcγRIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenvironments. Immunology 1998;94:56-63.
8. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, et al. Arthritis critically dependent on innate immune system players. Immunity 2002;16:157-68.
9. Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B-lymphocytes. Rheumatology 2001;40:205-11.
10. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999;52:1701-4.
11. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952-7.
12. Patel K, Berman J, Ferber A, Caro J. Refractory autoimmune thrombocytopenic purpura treatment with rituximab. Am J Hematol 2001;67:59-60.
13. Leandro MJ, Edwards JCW, Isenberg D. An open study of B-lymphocyte depletion in systemic lupus erythematosus [abstract]. Rheumatology 2002;41 Suppl 1:P18.
14. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development [abstract]. Semin Oncol 2002;29 Suppl 2:105-12.
15. Leandro MJ, Edwards JCW, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B-lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
16. Reff ME, Carnet K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B-lymphocytes in vivo by a chimaeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
17. Maloney DG, Grillo-Lopez AJ, Bodkin DJ. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-74.
18. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
19. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-lymphocyte lymphoma [abstract]. Semin Oncol 1999;26 Suppl 14:88-96.
20. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999;134:445-50.
21. Alwayn IP, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, et al. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B-cells does not result in significantly decreased production of anti-alpha Gal antibody. Xenotransplantation 2001;8:157-71.
22. Mannik M, Nardella FA. IgG rheumatoid factors and self-association of these antibodies. Clin Rheum Dis 1985;11:551-72.
23. Reparon-Schuijt CC, van Esch WJE, van Kooten C, Schellekens GA, de Jong BAW, van Venrooij WJ, et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 2001;44:41-7.
24. Corrigall VM, Bodman-Smith MD, Fife MS, Canas B, Myers LK, Wooley P, et al. The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol 2001;166:1492-8.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
26. Swedler W, Wallman J, Froelich C, Teodorescu M. Routine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity and predictive value for rheumatoid arthritis. J Rheumatol 1997;24:1037-44.
27. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
28. Specks U, Fervenza FC, McDonald TJ, Hogan MCE. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836-40.
29. McLaughlin P. Rituximab: perspective on single agent experience, and future directions in combination trials. Crit Rev Oncol Hematol 2001;40:3-16.
30. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol 2000;18:3135-43.
31. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511-3.
32. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders [abstract]. Semin Oncol 2000;27 Suppl 12:79-85.
33. Manz RA, Radbruch A. Plasma cells for a lifetime? Eur J Immunol 2001;32:923-7.
34. Maini RN, Elliott M, Brennan FM, Williams RO, Feldmann M. TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis. APMIS 1997;105:257-63.